De forventer 9-12 måneder for behandling hos EMA slik jeg forstod det tidligere.
Regulatory process for Xlucane™
The Biologics License Application for Xlucane™ was submitted to the FDA at the end of March 2022. We are now closely
following the regulatory processes for Xlucane™ in both
Europe and the US. We will communicate if the FDA, after the
validation process, accepts the application including and
the so called PDUFA date, which is the date when the FDA is
expected to decide on potential approval of the application.
The Marketing Authorization Application was submitted
to the EMA in September 2021, and we have now, in April,
responded to the questions that were addressed to us as
scheduled after day 120 of the registration process.